RYTM Stock Analysis: Rhythm Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 7.831m USD | 12M Return: 72.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 93.5M
Qual. Beats: 0
Rev. Trend: 98.0%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company developing treatments for rare neuroendocrine diseases, with a primary focus on genetic and syndromic forms of obesity. Its lead product, IMCIVREE (setmelanotide), is a melanocortin-4 receptor (MC4R) agonist approved for several ultra-rare conditions including POMC, LEPR deficiency obesity, Bardet-Biedl and Alström syndromes, Prader-Willi syndrome, and hypothalamic obesity. The company is headquartered in Boston, Massachusetts, was founded in 2008 (formerly known as Rhythm Metabolic, Inc.), and trades on NASDAQ as RYTM within the Biotechnology sub-industry.
The companys pipeline extends IMCIVREEs label into additional obesity indications (Phase 3) and includes earlier-stage assets such as the oral MC4R agonist bivamelagon (Phase 2) and the next-generation peptide agonist RM-718 (Phase 1). Rhythm operates within the rare disease biopharma segment, where therapies typically target small patient populations and frequently qualify for orphan drug designation, supporting extended market exclusivity and premium pricing.
- IMCIVREE revenue accelerates on expanded rare obesity approvals
- Phase 3 hypothalamic obesity data could unlock label expansion
- Oral bivamelagon pipeline advances target broader MC4R market
| Net Income: -202.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA 13.66 > 1.0 |
| NWC/Revenue: 150.5% < 20% (prev 188.1%; Δ -37.59% < -1%) |
| CFO/TA -0.27 > 3% & CFO -119.5m > Net Income -202.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.0m) vs 12m ago 7.79% < -2% |
| Gross Margin: 89.41% > 18% (prev 89.62%; Δ -0.21% > 0.5%) |
| Asset Turnover: 52.39% > 50% (prev 35.39%; Δ 17.00% > 0%) |
| Interest Coverage Ratio: -9.21 > 6 (EBIT TTM -182.0m / Interest Expense TTM 19.8m) |
| A: 0.74 (Total Current Assets 430.1m - Total Current Liabilities 103.2m) / Total Assets 442.3m |
| B: -3.18 (Retained Earnings -1.41b / Total Assets 442.3m) |
| C: -0.44 (EBIT TTM -182.0m / Avg Total Assets 414.5m) |
| D: 0.38 (Book Value of Equity 122.9m / Total Liabilities 319.4m) |
| Altman-Z'' = -8.07 = D |
| DSRI: 1.21 (Receivables 34.2m/17.8m, Revenue 217.2m/136.9m) |
| GMI: 1.00 (GM 89.62% / 89.41%) |
| AQI: 0.53 (AQ_t 0.02 / AQ_t-1 0.04) |
| SGI: 1.59 (Revenue 217.2m / 136.9m) |
| TATA: -0.19 (NI -202.7m - CFO -119.5m) / TA 442.3m) |
| Beneish M = -2.73 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 114.46 with a total of 998,559 shares traded. Over the past week, the price has changed by +4.02%, over one month by +33.21%, over three months by +32.08% and over the past year by +72.41%.
Current recommended Stop Loss: 107.80 (which is 5.8% or 1.4 ATR below the current price).
Rhythm Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RYTM.
- StrongBuy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 139.5 | 21.9% |
P/S = 36.0617
P/B = 61.6252
Revenue TTM = 217.2m USD
EBIT TTM = -182.0m USD
EBITDA TTM = -180.8m USD
Long Term Debt = 216.2m USD (estimated: total debt 227.0m - short term 10.8m)
Short Term Debt = 10.8m USD (from shortTermDebt, last quarter)
Debt = 230.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.84m
Net Debt = -109.8m USD (calculated: Debt 230.9m - CCE 340.6m)
Enterprise Value = 7.72b USD (7.83b + Debt 230.9m - CCE 340.6m)
Interest Coverage Ratio = -9.21 (Ebit TTM -182.0m / Interest Expense TTM 19.8m)
EV/FCF = -61.59x (Enterprise Value 7.72b / FCF TTM -125.4m)
FCF Yield = -1.62% (FCF TTM -125.4m / Enterprise Value 7.72b)
FCF Margin = -57.73% (FCF TTM -125.4m / Revenue TTM 217.2m)
Net Margin = -93.33% (Net Income TTM -202.7m / Revenue TTM 217.2m)
Gross Margin = 89.41% ((Revenue TTM 217.2m - Cost of Revenue TTM 23.0m) / Revenue TTM)
Gross Margin QoQ = 88.09% (prev 91.61%)
Tobins Q-Ratio = 17.46 (Enterprise Value 7.72b / Total Assets 442.3m)
Interest Expense / Debt = 8.56% (Interest Expense 19.8m / Debt 230.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -143.7m (EBIT -182.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.72 (Total Current Assets 430.1m / Total Current Liabilities 115.5m)
Debt / Equity = 1.88 (Debt 230.9m / totalStockholderEquity, last quarter 122.9m)
Debt / EBITDA = 0.61 (negative EBITDA) (Net Debt -109.8m / EBITDA -180.8m)
Debt / FCF = 0.88 (negative FCF - burning cash) (Net Debt -109.8m / FCF TTM -125.4m)
Total Stockholder Equity = 99.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -48.90% (Net Income -202.7m / Total Assets 442.3m)
RoE = -203.2% (Net Income TTM -202.7m / Total Stockholder Equity 99.7m)
RoCE = -57.59% (EBIT -182.0m / Capital Employed (Equity 99.7m + L.T.Debt 216.2m))
RoIC = -42.40% (negative operating profit) (NOPAT -143.7m / Invested Capital 339.1m)
WACC = 8.16% (E(7.83b)/V(8.06b) * Re(8.20%) + D(230.9m)/V(8.06b) * Rd(8.56%) * (1-Tc(0.21)))
Discount Rate = 8.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.01 | Cagr: 7.33%
[DCF] Fair Price = unknown (Cash Flow -125.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.27 | # QB: 0
Revenue Correlation: 97.96 | Revenue CAGR: 67.92% | SUE: 1.12 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.84 | Chg30d=+0.00% | Revisions=-15% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.83 | Chg30d=+0.11% | Revisions=-15% | Analysts=11
EPS current Year (2026-12-31): EPS=-3.26 | Chg30d=+0.97% | Revisions=-21% | GrowthEPS=-4.8% | GrowthRev=+57.1%
EPS next Year (2027-12-31): EPS=-0.74 | Chg30d=+6.67% | Revisions=-18% | GrowthEPS=+77.2% | GrowthRev=+80.9%
[Analyst] Revisions Ratio: -21% (up=15, down=24)